Clinical Trial

An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy

Study acronym: AMH
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 6, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Hereditary transthyretin amyloidosis (ATTRv) is a genetic, progressive and disabling disease that affects multiple organs and severely compromises the quality of life of patients and their families. A holistic approach is essential, which, in addition to early diagnosis and clinical management, includes psychological support to address the emotional and psychosocial impact of the disease. Although specific interventions for mental well-being are recommended, studies evaluating support tools for patients with ATTRv cardiomyopathy and their caregivers are lacking.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-26.
Trial Details
NCT Number NCT06907186
Lead Sponsor Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions Hereditary Transthyretin Amyloidosis
Enrollment 150 participants
Start Date 2024-05-24
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-06